CARGO Therapeutics (CRGX) and Its Rivals Financial Survey

CARGO Therapeutics (NASDAQ:CRGX) is one of 280 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare CARGO Therapeutics to related businesses based on the strength of its valuation, risk, earnings, institutional ownership, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CARGO Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-50.68%	-38.69%
CARGO Therapeutics Competitors	-5,175.29%	-173.59%	-43.23%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CARGO Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	0	0	7	0	3.00
CARGO Therapeutics Competitors	1581	4717	12215	235	2.59

CARGO Therapeutics presently has a consensus price target of $30.33, suggesting a potential upside of 44.72%. As a group, “Biological products, except diagnostic” companies have a potential upside of 63.65%. Given CARGO Therapeutics’ competitors higher possible upside, analysts plainly believe CARGO Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares CARGO Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CARGO Therapeutics	N/A	-$98.15 million	-0.41
CARGO Therapeutics Competitors	$567.60 million	-$32.27 million	-21.55

CARGO Therapeutics’ competitors have higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

CARGO Therapeutics beats its competitors on 7 of the 12 factors compared.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.